Lupin announced that China's National Medical Products Administration (NMPA) has approved its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine market. This marks Lupin's first product entry into China—a significant milestone in its global expansion.

Oseltamivir Phosphate for oral suspension, 6 mg/mL will be launched and commercialised to expand access, particularly for pediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.

Fabrice Egros, President—Corporate Development, Lupin, said, "We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world's largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, particularly in pediatric care. We look forward to building a stronger presence in this market through our partnership."

Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated for treatment of influenza A and B in patients 2 weeks of age and older, and for prevention of influenza A and B in individuals 1 year of age and older.

Wei Ren, President, Yabao, said, "We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao's dedication to quality pediatric medicines and showcases our strong collaboration. We will further expand our R&D portfolio for pediatric and adult chronic disease drugs to jointly advance our businesses."